Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?

S. Sreekanth, Jonathan Gibson

Research output: Unpublished contribution to conferenceAbstractpeer-review



Abstract - Purpose:Serial intravitreal ranibizumab injections are the main treatment for wet age- related macular degeneration (AMD), and patients are monitored by optical coherence tomography (OCT). Our objective in conducting this study is to determine whether serial intravitreal injections of ranibizumab in eyes with wet AMD alter the vitreo-macular interface (VMI)

Methods - Using a Topcon Spectral Domain OCT, we performed a prospective, observational study of 87 eyes of 82 consecutive patients undergoing treatment with intravitreal ranibizumab for wet AMD, with each patient followed up for a minimum of 6 months. The mean number of intravitreal ranibizumab injections was 4.28, range 3-6. Using macular OCT scans, the area of VMI was closely examined, for vitreo-macular adhesion (VMA), defined as perifoveal posterior vitreous detachment (PVD) with posterior vitreous attached to fovea. Any OCT separation of posterior vitreous face was observed and measured, every month for 6 months.

Results - There was no change in the OCT appearance or measurement of VM interface in 80 eyes (92%). VM adhesion, defined on OCT as when the posterior hyaloid line is attached to inner foveal surface and dettached perifoveally, was identified in 7 out of 87 treated eyes (8%) .Of these 7 eyes, 1 eye developed complete PVD following three injections, 1 eye developed partial PVD and the remaining 5 eyes had no significant change in VM adhesion.

Conclusions - To our knowledge this is the first study that has examined the VM interface following serial ranibizumab injections for wet AMD. This small pilot study suggests that most cases undergoing ranibizumab therapy suffer no disturbance to VM interface.
Original languageEnglish
Publication statusPublished - 11 Apr 2010
EventArvo 2010 - Fort Lauderdale, United States
Duration: 2 May 20106 May 2010


ConferenceArvo 2010
Country/TerritoryUnited States
CityFort Lauderdale


  • age-related macular degeneration
  • injection
  • vitreous


Dive into the research topics of 'Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?'. Together they form a unique fingerprint.

Cite this